Lung Cancer News

Proton beam radiotherapy with concurrent chemoradiotherapy appeared safe and effective among patients with advanced non-small cell lung cancer, according to results of a phase 2 prospective study.

Recommended genomic profiling for EGFR and ALK appeared inconsistent and underused among patients diagnosed with non-small cell lung cancer at community-based practices, according to published findings.

Single-agent atezolizumab appeared safe and effective across lines of therapy in patients with PD-L1–expressing non–small cell lung cancer, according to results from the global, multicenter, single-arm, open-label phase 2 BIRCH trial.

An FDA advisory committee today expressed unanimous support of ABP 215, a biosimilar candidate to bevacizumab.

CHICAGO — Brigatinib led to substantial activity in patients with ALK-positive, crizotinib-refractory non–small cell lung cancer, according to results presented at the ASCO Annual Meeting.

Adults treated with a combination of aspirin and clopidogrel demonstrated a reduced risk for a wide range of cancers on long-term follow-up compared with aspirin only or no treatment, according to a study published in The American Journal of Medicine.

Ceritinib appeared safe and effective in patients with ROS1–rearranged non–small cell lung cancer, according to a multicenter, open-label phase 2 study.

Brigatinib led to favorable intracranial and whole-body response rates and potent PFS for patients with ALK–positive, crizotinib-refractory non–small cell lung cancer, according to results of the phase 2 ALTA clinical trial.

The FDA approved use of dabrafenib in combination with trametinib for treatment of patients with metastatic non–small cell lung cancer whose tumors harbor BRAF V600E mutations, according to the agents’ manufacturer.

Nivolumab did not result in longer PFS than platinum-based chemotherapy as first-line treatment for stage IV or recurrent non–small cell lung cancer in patients with a PD-L1 expression level of 5% or more, according to an open-label phase 3 study published in The New England Journal of Medicine.